CSIMarket Company Name, Ticker, Customers, else..
 
Biodexa Pharmaceuticals Plc  (NASDAQ: BDRX)
 
Price: $1.2900 $0.63 95.455%
Day's High: $1.4600000381469727 Week Perf: 52.12 %
Day's Low: $ 0.83 30 Day Perf: -14 %
Volume (M): 95,069,548 52 Wk High: $ 59.40
Volume (M$): $ 0 52 Wk Avg: $11.72
Open: $0.88 52 Wk Low: $0.61



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Biodexa Pharmaceuticals Plc is a publicly traded pharmaceutical company that specializes in the research, development, and production of innovative drugs and therapies. The company focuses on various therapeutic areas, including oncology, rare diseases, immunology, and neurology. Biodexa Pharmaceuticals is known for its commitment to scientific excellence, utilizing cutting-edge technologies and partnerships with academia and research institutions to drive innovation in drug discovery. The company's goal is to improve the quality of life for patients worldwide by providing effective and safe treatment options. Biodexa Pharmaceuticals is dedicated to ethical and sustainable practices, ensuring that its operations are environmentally friendly and socially responsible.


   Company Address: 1 Caspian Point Cardiff 0
   Company Phone Number: 2048 0180   Stock Exchange / Ticker: NASDAQ BDRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD        0.13% 
ARDX   -2.56%    
MNKD   -4.29%    
PBYI   -4.89%    
TEVA   -1.47%    
VTRS   -2.95%    
• View Complete Report
   



Clinical Study

Biodexa Pharmaceuticals Announces Positive Phase I Results for Diffuse Midline Glioma Treatment, Offering New Hope for Patients

Published Fri, Feb 23 2024 1:30 PM UTC

Biodexa Pharmaceuticals PLC Presents Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D UpdateIn a recent press release, Biodexa Pharmaceuticals PLC (Biodexa) announced the positive top line results of its phase I clinical trial for the treatment of Diffuse Midline Glioma (DMG). This groundbreaking research offers hope for patients ...
Equity Market Information

Biodexa Pharmaceuticals PLC Raises $6.0 Million in Public Offering, Ushering in a New Era of Innovative Therapeutics

Published Thu, Dec 21 2023 9:00 PM UTC

Biodexa Pharmaceuticals PLC Successfully Closes $6.0 Million Public Offering, Demonstrating Investor Confidence in Innovative Therapeutics

Biodexa Pharmaceuticals PLC(Biodexa or the Company)

In a stellar display of market interest and investor confidence, Biodexa Pharmaceuticals PLC (Biodexa) successfully concluded its underwritten public offering, raising...
Partnership

Biodexa Pharmaceuticals PLC Leads the Charge in Innovative Glioblastoma Treatment Study while Surpassing Competitors in Revenue Growth

Published Tue, Oct 3 2023 12:30 PM UTC



In a groundbreaking development within the pharmaceutical industry, Biodexa Pharmaceuticals PLC (Biodexa) has successfully completed the recruitment for Cohort A in its study of MTX110, a potential treatment for recurrent glioblastoma. Simultaneously, the company has exceeded expectations by achieving a remarkable revenue increase in the fourth quarter of 2022. Thi...
Partnership

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)

Published Thu, Sep 21 2023 12:30 PM UTC


Biodexa Pharmaceuticals PLC (Biodexa or the Company) will be sharing exciting updates regarding their ongoing clinical trial, the Phase 1 study of MTX-110 (MAGIC-G1 Study), during the upcoming 2023 Annual European Association of Neuro-Oncology Meeting (EANO). This groundbreaking research focuses on patients suffering from recurrent glioblastoma, an aggressive and often ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.89
Working Capital Ratio 2.72
Leverage Ratio (MRQ) 0.59
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -580,364
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.